IDegLira, LixiLan Go Head-to-head as FDA OKs Both for Diabetes IDegLira, LixiLan Go Head-to-head as FDA OKs Both for Diabetes

The first approval for GLP-1 agonist lixisenatide/insulin glargine combo from Sanofi for type 2 diabetes in US will be marketed as Soliqua. Novo Nordisk product Xultophy combines liraglutide and insulin degludec.FDA Approvals
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news